Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 3/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30032895 | 1.00 | PYGL (0.47) | PYGLGRIK1CA1CA2CA12 | |
| SCHEMBL30419489 | 1.00 | PYGL (0.47) | PYGLGRIK1CA1CA2CA12 | |
| SCHEMBL30031290 | 0.86 | KCNMA1 (0.47) | PYGLGRIK1CA1CA2CA12 | |
| SCHEMBL23796288 | 0.86 | KCNMA1 (0.47) | PYGLGRIK1CA1CA2CA12 | |
| SCHEMBL28877541 | 0.84 | ALDH1A1 (0.41) | PYGLCA1CA2CA12CA7 | |
| SCHEMBL30032529 | 0.83 | CA1 (0.45) | PYGLCA1CA2CA12CA7 | |
| SCHEMBL163610 | 0.79 | CA1 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL23796850 | 0.78 | KMT2A (0.49) | GRIK1ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL24054614 | 0.77 | HDAC1 (0.43) | PYGLGRIK1PTGS2ALDH1A1MEN1 | |
| SCHEMBL1498023 | 0.77 | CA1 (0.56) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4118069-B1 | PARA-HYDROQUINONE DERIVATIVES AS VEGF, TNF AND/OR IL INHIBITORS FOR THE TREATMENT OF NEUROINFLAMMATORY DISEASES | OM PHARMA SA (CH) | 2024-10-23 | — | — | EP | disclosed |
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2023-05-18 | — | — | US | disclosed |
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2023-05-18 | — | — | US | disclosed |
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2023-05-18 | — | — | US | disclosed |
| EP-4118069-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM Pharma SA (CH) | 2023-01-18 | — | — | EP | disclosed |
| WO-2021180655-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2021-09-16 | — | — | WO | disclosed |
| EP-3878837-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM Pharma SA (CH) | 2021-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | HRH4, NCOA4, HRH3 | PYGL 3265/4885GRIK1 2627/4885CA1 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.